Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease

Overview of attention for article published in Frontiers in immunology, July 2024

Altmetric Badge

Mentioned by

twitter: 1 X user

So far, Altmetric has seen 1 X post from an account with 1,225 followers.

https://t.co/sd4VAVCCPA

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.